• 1
    Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis. 2006; 26: 15361.
  • 2
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 42942.
  • 3
    Vizzini GB, Luca A, Marino IR. Hepatitis B virus reactivation after a single session of transarterial chemoembolization in patients with hepatocellular carcinoma. Ann. Intern. Med. 2003; 138: 6912.
  • 4
    Jang JW, Choi JY, Bae SH et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J. Hepatol. 2004; 41: 42735.
  • 5
    Park JW, Park KW, Cho SH et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am. J. Gastroenterol. 2005; 100: 2194200.
    Direct Link:
  • 6
    Xu J, Wang YH, Xia JL et al. Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients. Chin. J.Cancer 2009; 28: 15.
  • 7
    Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg. Today 2010; 40: 793808.
  • 8
    Kubo S, Nishiguchi S, Hamba H et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann. Surg. 2001; 233: 13945.
  • 9
    Huang L, Li J, Lau WY et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2012; 27: 15864.
  • 10
    Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J. Gastroenterol. Hepatol. 2011; 26: 62838.
  • 11
    Wong JS, Wong GLH, Tsoi KK et al. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment. Pharmacol. Ther. 2011; 33: 110412.
  • 12
    Chuma M, Hige S, Kamiyama T et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J. Gastroenterol. 2009; 44: 9919.
  • 13
    Hung IF, Poon RT, Lai CL et al. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am. J. Gastroenterol. 2008; 103: 166373.
    Direct Link:
  • 14
    Koda M, Nagahara T, Matono T et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern. Med. 2009; 48: 1117.
  • 15
    Kubo S, Tanaka H, Takemura S et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol. Res. 2007; 37: 94100.
  • 16
    Kuzuya T, Katano Y, Kumada T et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 192935.
  • 17
    Li N, Lai EC, Shi J et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann. Surg. Oncol. 2010; 17: 17985.
  • 18
    Piao CY, Fujioka S, Iwasaki Y et al. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma—using an untreated, matched control cohort. Acta Med. Okayama 2005; 59: 21724.
  • 19
    Shuqun C, Mengchao W, Han C et al. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006; 53: 24952.
  • 20
    Yoshida H, Yoshida H, Goto E et al. Safety and efficacy of lamivudine after radiofrequency ablation in patients with hepatitis B virus-related hepatocellular carcinoma. Hepatol. Int. 2008; 2: 8994.